US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp Warrant

0.0120

0.0000

Volume:- -

Turnover:- -

Market Cap:89.32K

PE:0.00

High:0.0120

Open:0.0120

Low:0.0120

Close:0.0120

52wk High:0.1198

52wk Low:0.0100

Shares:7.44M

Float Shares:7.44M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.2115

ROE:-8.41%

ROA:-10.52%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

THOMSON REUTERS

Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028

THOMSON REUTERS

Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each

THOMSON REUTERS

Pasithea Therapeutics Corp - Safety Review Committee Recommends Escalation to Cohort 8

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients, With Positive Safety, Pharmacokinetic (Pk), and Pharmacodynamic (Pd) Data

THOMSON REUTERS

Pasithea Therapeutics Announces Positive Pas-004 Tablet Pharmacokinetic (Pk) Data in Ongoing Phase 1/1B Trial in Adult Nf1 Patients

THOMSON REUTERS

Pasithea Therapeutics Corp - Tablet Pk Exposure Increases Proportionally With Dose

THOMSON REUTERS

BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation

Pasithea Therapeutics Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Its Ongoing Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS

Pasithea Therapeutics Corp - Interim Data From First Two Cohorts Expected Q1 2026

THOMSON REUTERS

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort From Its Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KTTAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp Warrant","latestPrice":0.012,"timestamp":1771621200000,"preClose":0.012,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":7443563,"shares":7443563,"eps":-5.2115,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 EST","open":0.012,"high":0.012,"low":0.012,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.2115,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1631678400000,"exchange":"NASDAQ","adjPreClose":0.012,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","floatShares":7443563,"roa":"-10.52%","roe":"-8.41%","lyrEps":0,"shares":7443563,"dividePrice":0,"high":0.012,"amplitude":0,"preClose":0.012,"low":0.012,"week52Low":0.01,"pbRate":"0.00","psRate":"2.11","week52High":0.1198,"institutionHeld":0,"latestPrice":0.012,"eps":-5.2115,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.2115,"open":0.012,"prevYearClose":0.0141,"prevWeekClose":0.0137,"prevMonthClose":0.0142,"prevQuarterClose":0.0141,"fiveDayClose":0.0137,"twentyDayClose":0.0145,"sixtyDayClose":0.0123},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTAW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTAW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588030805","title":"Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030805?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7a5901a9f1bb5fc4fa7bc7230f7ede9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA2KL4GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"2586498738","title":"Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2586498738","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586498738?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:20","pubTimestamp":1764339600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nTUA3FKTBW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTAW","KTTA"],"gpt_icon":0},{"id":"2586373849","title":"Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2586373849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586373849?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:20","pubTimestamp":1764339600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nTUA3FKTBW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"2585461366","title":"Pasithea Therapeutics Corp - Safety Review Committee Recommends Escalation to Cohort 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461366?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA8QRR4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2585461360","title":"Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients, With Positive Safety, Pharmacokinetic (Pk), and Pharmacodynamic (Pd) Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461360?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA8QRR4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2585408371","title":"Pasithea Therapeutics Announces Positive Pas-004 Tablet Pharmacokinetic (Pk) Data in Ongoing Phase 1/1B Trial in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2585408371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585408371?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA89L6NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139","KTTAW"],"gpt_icon":0},{"id":"2585140843","title":"Pasithea Therapeutics Corp - Tablet Pk Exposure Increases Proportionally With Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2585140843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585140843?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA89L6NN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"2565541686","title":"BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2565541686","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565541686?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:45","pubTimestamp":1757331937,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) RecommendationSept 8 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"2565683124","title":"Pasithea Therapeutics Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Its Ongoing Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2565683124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565683124?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:01","pubTimestamp":1757329260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139","KTTAW"],"gpt_icon":0},{"id":"2565486683","title":"Pasithea Therapeutics Corp - Interim Data From First Two Cohorts Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2565486683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565486683?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:01","pubTimestamp":1757329260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2555884596","title":"Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort From Its Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2555884596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555884596?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:01","pubTimestamp":1753959660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUAB1LDSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}